Cardiac Toxicities Associated with Immune Checkpoints Inhibitors:Mechanisms, Manifestations and Management
- Author:
Abdulrazzak ZARIFA
1
;
Jin Wan KIM
;
Juan LOPEZ-MATTEI
;
Nicolas PALASKAS
;
Cezar ILIESCU
;
Peter Y. KIM
Author Information
- Publication Type:Review
- From:Korean Circulation Journal 2021;51(7):579-597
- CountryRepublic of Korea
- Language:English
- Abstract: Immune checkpoint inhibitor (ICI) associated cardiovascular adverse events (CVAE) have become more frequent with the growing use of cancer immunotherapy. CVAEs include a wide spectrum of diseases such as myocarditis, pericarditis, heart failure, arrhythmias, coronary artery disease, and hypertension. The induction of cardiovascular side effects by ICI use is hypothesized to occur due to inflammation and immune dysregulation of normal tissue in response to immunotherapy. Management of ICI-associated CVAEs mitigates an overactive immune response by utilizing steroids, immunomodulatory drugs and hemodynamic stabilization. However, few controlled studies on the cardiovascular safety of ICIs exist and treatment of their side effects are mostly from limited case series. Our review seeks to provide the most recent understanding of ICI-associated CVAEs and their management.
